Controlled Substance Top Companies-Recent Developments, Business Strategy, Deal Strategy, Patent Strategy, Benchmarking and Management Outlook

Controlled Substance Market Size Analysis and Top Companies

The global controlled substance market size is calculated at USD 93.70 billion in 2024 and is projected to hit around USD 157.64 billion by 2034 with a CAGR of 5.34% from 2024 to 2033. The top companies operating in the controlled substance market are Merck & Co. Inc, Johnson & Johnson, Orbis Biosciences, Aradigm Corporation, Corium International, G.W. Pharmaceuticals, Lannett and Others.

Market Scope

Controlled Substance Market Companies

• Merck & Co. Inc
• Johnson & Johnson
• Orbis Biosciences
• Aradigm Corporation
• Corium International
• G.W. Pharmaceuticals
• Lannett

Recent Developments

• In December 2022, a leading biotech company in the U.S., AbbVie, announced that the company received approval from the U.S. Food & Drug Administration (FDA) for its Cariprazine (Vraylar) as an adjunctive therapy for major depressive disorders in adults.
• In December, the government of Yukon, a Canadian territory, announced the expansion of pharma services. Pharmacists in Yukon can now access and prescribe controlled substance medicines for travel-related disorders.
• In December 2022, Spark Biomedical announced a strategic partnership with AcuityMD. The partnership aims to promote Spark’s noninvasive therapeutic to treat withdrawal symptoms caused due to opioid disorder. Spark’s therapy offers a controlled tool that sends mild impulses to the brain to help alleviate opiate symptoms.
• In December 2022, The New Zealand government amended the Misuse of Drugs Regulations 1997. The amendments will allow prescribers to issue signature-exempt prescriptions for controlled drug medicines. The controlled medication for ADHD will be covered by a single e-script which will be helpful for patients that have to visit G.P. for regular prescriptions from rural areas.
• In June 2022, Bicycle Health, a virtual opioid use disorder treatment startup, raised $50 million in a series B funding round led by InterAlpen Partners for virtual opioid use disorder treatment.
• In May 2022, the U.S. Food and Drug Administration (FDA) approved Quelbree, a non-stimulant medication for ADHD in adults. Quelbree received approval from the FDA in 2021 to treat ADHD in kids under six years of age.
• In April 2022, the government of Florida took a step towards expanding telemedicine facilities. The government decided to remove prior restrictions on prescription controlled substances in telemedicine. The new law in Florida now allows telemedicine prescriptions for controlled substances with very few and narrow exceptions. 

We have prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344